Malignant neoplasms are the fifth most common cause of death among children and adolescents aged 0–18 years and the third most common cause when excluding infants <1 year [1, 2]. With increasing evidence on gynaecologic malignancies, a better understanding in the molecular pathogenesis and major treatment advances with immune checkpoint inhibitors, targeted therapy and antibody-drug-conjugates for common malignancies, there remains a significant paucity of data for rare subtypes, including gynaecologic malignancies in children and adolescents.